Anandamide injected into the lateral ventricle of the brain inhibits submandibular salivary secretion by attenuating parasympathetic neurotransmission by Fernández Solari, José Javier et al.
537
Braz J Med Biol Res 42(6) 2009
Anandamide injected icv in the brain reduces salivation
www.bjournal.com.br
Brazili n Jour al of Medical and Biological Research (2009) 42: 537-544
ISSN 0100-879X
Anandamide injected into the lateral




J. Fernandez-Solari1,2, J.P. Prestifilippo1, P. Vissio3, M. Ehrhart-Bornstein4,
S.R. Bornstein4, V. Rettori1 and J.C. Elverdin2
1Center for Pharmacological and Botanical Studies, National Council of Scientific and Technical
Research, 2Department of Physiology, Dental School, 3Laboratory of Animal Embryology, Department of
Experimental Biodiversity and Biology, School of Sciences, University of Buenos Aires, Buenos Aires,
Argentina
4Department of Medicine Carl Gustav Carus, University Hospital, University of Dresden, Dresden,
Germany
Correspondence to: J. Fernandez-Solari, Center for Pharmacological and Botanical Studies
(CEFYBO-CONICET/UBA), Paraguay, 2155,1121 Buenos Aires, Argentina
Fax: +54-11-4508-3680. E-mail: javierfsolari@yahoo.com.ar
Our objective was to determine the effect of arachidonylethanolamide (anandamide, AEA) injected intracerebroventricularly
(icv) into the lateral ventricle of the rat brain on submandibular gland (SMG) salivary secretion. Parasympathetic decentralization
(PSD) produced by cutting the chorda tympani nerve strongly inhibited methacholine (MC)-induced salivary secretion while
sympathetic denervation (SD) produced by removing the superior cervical ganglia reduced it slightly. Also, AEA (50 ng/5 μL, icv)
significantly decreased MC-induced salivary secretion in intact rats (MC 1 μg/kg: control (C), 5.3 ± 0.6 vs AEA, 2.7 ± 0.6 mg; MC
3 μg/kg: C, 17.6 ± 1.0 vs AEA, 8.7 ± 0.9 mg; MC 10 μg/kg: C, 37.4 ± 1.2 vs AEA, 22.9 ± 2.6 mg). However, AEA did not alter the
significantly reduced salivary secretion in rats with PSD, but decreased the slightly reduced salivary secretion in rats with SD
(MC 1 μg/kg: C, 3.8 ± 0.8 vs AEA, 1.4 ± 0.6 mg; MC 3 μg/kg: C, 14.7 ± 2.4 vs AEA, 6.9 ± 1.2 mg; P < 0.05; MC 10 μg/kg: C, 39.5
± 1.0 vs AEA, 22.3 ± 0.5 mg; P < 0.001). We showed that the inhibitory effect of AEA is mediated by cannabinoid type 1 CB1
receptors and involves GABAergic neurotransmission, since it was blocked by previous injection of the CB1 receptor antagonist
AM251 (500 ng/5 μL, icv) or of the GABAA receptor antagonist, bicuculline (25 ng/5 μL, icv). Our results suggest that
parasympathetic neurotransmission from the central nervous system to the SMG can be inhibited by endocannabinoid and
GABAergic systems.
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Gamma-aminobutyric acid
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Introduction
The submandibular gland (SMG) is one of the major
salivary glands, together with the sublingual and the pa-
rotid glands. The secretion of saliva is controlled by the
autonomic nervous system. The parasympathetic nervous
system exerts its function through the activation of musca-
rinic cholinergic receptors in the salivary glands via im-
pulses through the chorda tympani nerve and the release
of acetylcholine; salivation then depends on the contrac-
tion of myoepithelial cells embracing the acini and interca-
lated ducts (1). The sympathetic nervous system also
induces salivary secretion by releasing norepinephrine
that stimulates α- and β-adrenergic receptors (2). It was
reported that pilocarpine, a muscarinic agonist, injected
intracerebroventricularly (icv) induced salivary secretion
by activating central autonomic efferent fibers (3). Other
studies suggest that an important center for eliciting sali-
vary secretion exists in the hypothalamus and involves
cholinergic pathways. Numerous projections exist from the
lateral hypothalamus to salivary nuclei located in the brain
stem (4,5). Lesions of the lateral or ventromedial hypo-
thalamus impair salivary secretion induced by increased
ambient temperature in rats (5,6). Also, other experiments
have demonstrated that warming or electrical stimulation
of the preoptic area produces an increase in salivary
secretion by the submandibular and sublingual glands (7),
and lesions in the anteroventral third ventricle region re-
duce salivary secretion induced by pilocarpine injected
intraperitoneally (ip) or icv (3).
The main psychoactive ingredient of Cannabis sativa,
Δ9-tetrahydrocannabinol (THC), affects different physiologi-
cal functions. Twenty years ago, two subtypes of G-pro-
tein-coupled cannabinoid (CB) receptors were identified:
the CB1 central receptor subtype, which is mainly ex-
pressed in the brain (8-10), and the CB2 peripheral recep-
tor subtype, which appears to be particularly abundant in
the immune system (11). A few years later, arachidonyl-
ethanolamide (anandamide, AEA) and arachidonoyl glyc-
erol, the best-known endocannabinoids, were discovered
and purified. Both endocannabinoids derive from arachi-
donic acid and bind with high affinity to CB receptors (12).
Selective antagonists have been developed for CB1 re-
ceptors, such as AM251 (13) and SR141716A (14,15), and
for CB2, such as AM630 (16) and SR144528 (17).
The salivary glands have secretory units, called acini,
which are continuous with a ductal system. We reported
previously that both CB1 and CB2 receptors are located in
the SMG, mainly in the ductal system, and CB2 receptors
have also been found in the acini (18). We also demon-
strated that AEA injected into the SMG decreases the
methacholine (MC)- and norepinephrine-stimulated sali-
vary secretion. These inhibitory effects of AEA were blocked
by injecting either the CB1 antagonist AM251 or AM630, a
CB2 antagonist, into the SMG, confirming the presence
and the biological effects of both CB1 and CB2 receptors in
the SMG (18).
In contrast to classical neurotransmitters, endocan-
nabinoids can function as retrograde synaptic messen-
gers. They are released from postsynaptic neurons and
travel backwards across synapses, activating CB1 recep-
tors on presynaptic axons and suppressing neurotransmit-
ter release (19). It has been demonstrated that THC de-
creased the electrically stimulated salivary flow in dogs by
a mechanism involving a decrease in acetylcholine re-
lease, which results in reduction of blood flow to the SMG
(20). There is evidence that AEA and THC abolished
norepinephrine release in other systems by presynaptic
inhibition (21). Also, it was reported that cholinergic neu-
rons of the hippocampus co-express CB1 and GABAB
receptors, suggesting a link between endocannabinoids
and gamma aminobutyric acid (GABA), the main inhibitory
neurotransmitter of the CNS (22). Therefore, it is possible
that the endocannabinoid system modulates salivary se-
cretion by acting not only directly on CB receptors in the
salivary glands but also on CB receptors in the brain that
could modulate the autonomic neurotransmission to the
glands.
It is also known that endocannabinoids produce differ-
ent effects by the activation of transient receptor potential
vanilloid type 1 (TRPV1) channels reported to be located in
the brain (23). Because TRPV1-expressing neurons were
observed in the hypothalamus (23), this kind of interaction
should also be considered to be a mechanism in the
central control of salivary secretion.
Since it is known that the consumption of cannabinoids
decreases salivary secretion and also alters synaptic neu-
rotransmission, the aim of the present study was to deter-
mine the effect of the endocannabinoid AEA, injected into
the lateral ventricle of the brain, on SMG salivary secretion.
Additionally, since it was reported that some effects of AEA
in the CNS were mediated by modulating GABAergic (24,25)
neurotransmission, we also studied the effects of AEA
when GABA receptors were blocked.
Material and Methods
Animals
Adult male Wistar rats (250–300 g) from our own colony
were kept in group cages in an animal room having a
photoperiod of 12 h of light (7:00 to 19:00 h), room temper-
ature of 22–25°C and free access to rat chow and tap water.
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The animals were divided into several experimental groups,
5-6 animals per group. The experimental procedures re-
ported here were approved by the Animal Care Committee
of the Center of Pharmacological and Botanical Studies,
National Council for Research of Argentina and carried out
according to NIH guidelines.
Salivary secretion studies
Salivary responses were determined in anesthetized
rats (100 mg/kg chloralose in 0.9% NaCl, iv). The main
duct of the right SMG was cannulated to obtain salivary
secretion. Since resting (non-stimulated) flow of saliva is
not observed in rats, the sialogogue MC was utilized to
induce salivary secretion. Different doses of MC (1, 3, and
10 μg/kg in saline) were sequentially injected via the right
femoral vein as previously described (26) and dose-re-
sponse curves (DRC) of salivary secretion from the right
SMGs were performed for each rat, before (control curves)
and after the treatments described in the following para-
graph. All control DRC were performed after the injection
of the vehicle of each drug. The saliva secreted over a
period of 3 min after the administration of each dose of MC
was collected on aluminum foil and weighed. The period
between two successive injections of MC was 5 min.
Results are reported as mg saliva per 3 min.
To evaluate the participation of brain CB receptors in
salivary secretion, a cannula was implanted into the lateral
cerebral ventricle under tribromoethanol anesthesia (3.5%
in saline, 1 mL/100 g animal body weight, ip) using a
stereotaxic instrument 1 week prior to the day of the
experiment. The coordinates relative to the interaural line
(AP -0.6 mm, L -2 mm, DV -3.2 mm) were taken from the
stereotaxic atlas of Pellegrino et al. (27). The adequate
location of the cannula in the ventricle was confirmed by
injecting a solution of methylene blue icv at the end of the
experiment and confirming its position in histologic sec-
tions.
Fifteen minutes after control DRC, when the vehicle
injected was saline containing 0.3% ethanol, AEA (50 ng/
5 μL, icv) was injected. Fifteen minutes later, DRC were
constructed to evaluate the effect of AEA on salivary
secretion. To study the effect of AEA when CB1 or CB2
receptors were blocked, AM251 (500 ng/5 μL, icv) or
AM630 (500 ng/5 μL, icv), respectively, was injected 15
min prior to the injection of AEA. AM251 and AM630 were
first dissolved in dimethylsulfoxide (DMSO) and further
dilutions were made in saline, with the vehicle being saline
with 10% DMSO. Additionally, the effect of AM251 and
AM630 alone was studied. To study the effect of AEA when
vanilloid receptors (TRPV1) were blocked, capsazepine (2
μg/5 μL), a vanilloid receptor selective antagonist, was
injected icv 15 min before the AEA. Capsazepine was also
dissolved in DMSO (10%). Additionally, the effect of
capsazepine alone was studied. To determine the effect of
AEA on salivary secretion when GABAA receptors were
blocked, we used bicuculline (25 ng/5 μL), which was
dissolved in saline and injected icv 15 min before the
injection of AEA. All studies were performed using 5-6 rats
per group.
Parasympathetic or sympathetic blockade studies
To produce parasympathetic blockade of the SMG, the
right chorda tympani nerve was cut, resulting in unilateral
parasympathetic decentralization (PSD), while, to produce
sympathetic blockade, the right superior cervical ganglia
(SCG) was removed resulting in unilateral sympathetic de-
nervation (SD), as previously described (28). To analyze the
acute effect of PSD and/or SD per se on salivary secretion,
the control DRC were constructed before the chorda tympani
was cut and/or the SCG was removed. Thirty minutes after
PSD and/or SD, the second DRC were constructed. To
study the effect of AEA on PSD or SD rats, control DRC of
salivary secretion from the right SMG were constructed for
each animal 30 min after surgery. Fifteen minutes later, AEA
was injected icv, and after an additional 15 min, the second
DRC were constructed as described above.
Statistical analysis
Data are reported as means ± SEM for 5-6 rats per
group. The results obtained from salivary studies were ana-
lyzed by two-way ANOVA followed by the Bonferroni post-
test. All analyses were conducted using the Prism software
(GraphPad Software, Inc., USA). Differences with P values
<0.05 were considered to be statistically significant.
Immunohistochemistry
The rats were anesthetized with tribromoethanol and
perfused with 4% paraformaldehyde and 0.17% picric acid
in PBS (0.05 M, pH 7.4) for 30 min. After perfusion, the
hypothalami were dissected and post-fixed. Transverse
slices (10 μm) were cut with a cryostat and collected on
gelatin-coated slides. Primary antibodies against CB1 re-
ceptors (1:1000) raised in rabbits were used (Affinity
BioReagents, Inc., USA). Sections were developed using
a secondary anti-rabbit antibody raised in goats (1:200)
coupled to rhodamine (Vector Laboratories, UK). The slides
were examined and the images were captured using a
confocal laser microscope (Nikon C1, objective lenses
Nikon 60X 1.40 Plan Apo, USA).
Chemicals
Bicuculline methobromide and arachidonylethanola-
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Figure 1. Effect of sympathetic denervation (SD), parasympa-
thetic decentralization (PSD), and PSD plus SD on Δ saliva
between control and post-treatment curves of methacholine-
stimulated salivary secretion. Data are reported as means of Δ
saliva ± SEM for 5 rats. *P < 0.05 vs SD (two-way ANOVA
followed by the Bonferroni post-test).
mide (anandamide, AEA) were purchased from Sigma
(USA). Chloralose and methacholine (MC) were obtained




oxyphenyl)methanona] and capsazepine [N-[2-(4-chloro-
phenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-
benzazepine-2-carbothioamide] were obtained from
Tocris™ (Ellisville, USA).
Results
Effect of PSD and/or SD on MC-stimulated salivary
secretion
Unilateral PSD decreased dramatically salivary secre-
tion induced by MC as demonstrated by Δ saliva between
post-treatment and control curves (Figure 1). However,
unilateral SD decreased only slightly MC-induced salivary
secretion. When PSD was followed by SD, the decrease of
salivary secretion was not modified significantly as com-
pared to PSD alone. Moreover, Δ saliva was significantly
higher in PSD and PSD plus SD rats compared to SD rats,
when secretion was induced by 3 and 10 μg/kg of MC.
Effect of AEA injected icv on MC-stimulated salivary
secretion in intact rats or in rats with PSD or with SD
Intracerebroventricular injections of AEA (50 ng/5 μL)
reduced MC-induced salivary secretion in a statistically
significant manner (Figure 2A). However, AEA had no
effect on MC-induced salivary secretion in rats that lacked
Figure 2. Effect of anandamide (AEA) (50 ng/5 μL) injected icv
on methacholine-stimulated salivary secretion in intact rats (A)
and in rats with parasympathetic decentralization (PSD) (B) or
with sympathetic denervation (SD) (C). Data are reported as
means ± SEM for 5-6 rats. *P < 0.05 vs vehicle injections (two-
way ANOVA followed by the Bonferroni post-test).
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parasympathetic inputs to the right SMG (PSD rats; Figure
2B). In animals without sympathetic inputs to the right SMG
(SD rats), AEA inhibited the MC-induced salivary secre-
tion, as observed in intact rats (Figure 2C).
Effect of AEA, AM251 and bicuculline injected icv on
MC-stimulated salivary secretion
Intracerebroventricular injections of AM251, a CB1
receptor antagonist (500 ng/5 μL), 15 min before the injec-
tion of AEA, blocked the inhibitory effect of AEA on MC-
induced salivary secretion (Table 1). The injection of AM251
alone did not significantly alter MC-induced salivary secre-
tion compared to control curves constructed before the
injection of the antagonist. We also showed that the inhib-
itory effect of AEA on MC-induced salivary secretion was
prevented completely by injecting bicuculline (25 ng/5 μL,
icv ), a GABAA receptor blocker, 15 min prior to the injection
of AEA (Table 1).
Effect of AEA, AM630 and capsazepine injected icv on
MC-stimulated salivary secretion
Neither injections of AM630 (500 ng/5 μL vehicle, icv ),
a CB2 receptor antagonist, nor injections of capsazepine
(2 μg/5 μL vehicle, icv ), a vanilloid receptor antagonist, 15
min before the injection of AEA, prevented the inhibitory
effect of AEA on MC-induced salivary secretion (Table 2).
Neither AM630 nor capsazepine alone modified MC-in-
duced salivary secretion.
Hypothalamic localization of CB1 receptors
Immunohistochemical studies showed a high density
of cells and fibers immunostained for CB1, distributed in
the lateral area of the hypothalamus, a zone involved in the
regulation of salivary secretion (Figure 3).
Discussion
Sialogogues can act on hypothalamic receptors to
induce salivation (29-31). Moreover, it has been reported
that the muscarinic antagonist atropine injected icv re-
duced salivation induced by the muscarinic agonist pilo-
carpine injected ip, suggesting that pilocarpine enters the
brain and acts on central muscarinic receptors, activating
autonomic efferent fibers to induce salivation (3,31). Addi-
Table 2. Effect of anandamide, AM630 and/or capsazepine injected icv on methacholine (MC)-stimulated salivary secretion.
MC (μg/kg) Saliva (mg/3 min)
AM630 + AEA AM630 Capsazepine + AEA Capsazepine
Pre Post Pre Post Pre Post Pre Post
1 5.5 ± 0.5 3.2 ± 0.6* 5.1 ± 0.8 5.2 ± 1.1 5.5 ± 0.8 3.1 ± 0.7* 5.1 ± 0.5 5.0 ± 0.7
3 21.5 ± 1.5 11.5 ± 0.5* 21.9 ± 1.3 22.5 ± 1.6 22.3 ± 1.1 9.1 ± 0.4* 19.2 ± 1.5 17.0 ± 1.2
10 43.0 ± 2.0 23.0 ± 2.0* 41.2 ± 2.6 39.9 ± 3.0 40.8 ± 1.7 20.4 ± 1.0* 38.6 ± 2.4 36.5 ± 1.5
Data (mg saliva/3 min) are reported as means ± SEM for N = 5-6 animals. The doses of anandamide (AEA), AM630 and capsazepine
were 50, 500 and 2 μg/5 μL, respectively. *P < 0.05 vs vehicle injection (two-way ANOVA followed by the Bonferroni post-test).
Table 1. Effect of anandamide, AM251 and/or bicuculline injected icv on methacholine (MC)-stimulated salivary secretion.
MC Saliva (mg/3 min)
(μg/kg)
AEA AM251 + AEA AM251 Bicuculline + AEA Bicuculline
Pre Post Pre Post Pre Post Pre Post Pre Post
1 5.3±0.6 2.7±0.6* 6.3±1.3 5.2±1.1 4.2±1.0 4.7±1.5 5.0±0.6 7.8±0.2 5.2±1.6 7.3±1.8
3 17.8±1.0 8.7±0.8* 18.1±2.2 12.6±2.0 17.0±3.0 18.0±3.8 17.7±1.5 15.3±0.9 17.0±2.3 22.3±0.7
10 37.4±1.2 22.9±2.5* 37.0±3.3 30.2±4.4 38.0±1.2 41.7±1.7 38.9±1.0 36.5±0.9 36.3±2.0 42.3±2.3
Data (mg saliva/3 min) are reported as means ± SEM for N = 5-6 animals. The doses of anandamide (AEA), AM251 and bicuculline
were 50, 500 and 25 ng/5 μL, respectively. *P < 0.05 vs vehicle injection (two-way ANOVA followed by the Bonferroni post-test).
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tionally, it was shown that the β-adrenoreceptor agonist
isoproterenol injected icv increased salivary flow, demon-
strating the participation of a central adrenergic system in
the regulation of salivary secretion (32). Moreover, re-
moval of the SCG as well as systemic injection of α-
adrenoceptor antagonists reduced the icv pilocarpine–stim-
ulated salivation by 40% compared to sham-operated rats
(33). This evidence suggests that sympathetic nerves
involved in salivary secretion could be stimulated by direct
activation of brain cholinergic receptors. Therefore, sialo-
gogues injected through the femoral vein act not only on
their receptors in the SMG, but also on their receptors in
the brain, stimulating efferent responses at the periphery.
The present study demonstrates for the first time that
AEA centrally inhibits salivary secretion by acting on CB1
receptors located in the brain and thus, decreasing para-
sympathetic neurotransmission to the SMG, additionally to
the local action on CB1 and CB2 receptors in the SMG,
previously reported (18). We first evaluated the effect of
parasympathetic decentralization or of sympathetic dener-
vation and of both situations together in order to determine
the degree of participation of both autonomic divisions in
the induction of salivation. The results showed that para-
sympathetic decentralization by cutting the chorda tympani
greatly decreased the saliva secretion induced by MC. On
the other hand, sympathetic denervation decreased saliva
secretion only slightly.
There are abundant reports describing the effects of
exo- and endocannabinoids on autonomic neurotransmis-
sion. It was reported that the activation of CB1 receptors by
THC and AEA causes hypotension via a sympatho-inhibi-
tory action in rats (21). These effects are related to presyn-
aptic inhibition of norepinephrine exocytosis, since AEA
and THC abolish norepinephrine release from isolated rat
atria and vasa deferentia, and SR141716A, a selective
CB1 antagonist, competitively reversed these effects.
Moreover, WIN55212-2 and CP55940, synthetic cannabi-
noid receptor agonists, inhibited presynaptically the sym-
pathetic cardio-accelerator response in the rabbit by acti-
vating heart CB1 receptors (34). Also, bradycardia evoked
by stimulating the vagus nerve was inhibited by WIN55212-
2 and CP55940 through CB1 receptors. Our results sug-
gest that AEA injected icv inhibits salivary secretion by
decreasing parasympathetic neurotransmission, with no
effect on sympathetic neurotransmission, since there was
no inhibitory effect in addition to that produced by severing
the chorda tympani nerve. Along the same line, when the
SCG was removed, the injection of AEA decreased saliva-
tion to an extent similar to that observed in rats without
surgery.
Additionally, we showed by immunohistochemistry the
presence of CB1 receptors in the lateral hypothalamus,
which is an important area for the control of salivary secre-
tion (4,5). These results agree with other publications that
demonstrated the presence of specific binding for CB1
receptors in the lateral hypothalamic area (35). Further-
more, we demonstrated that the inhibitory effect of AEA on
salivary secretion was mediated by activation of CB1 re-
ceptors, since AM251, a CB1 specific antagonist, blocked
this inhibitory effect. The Ki of AM251 and AEA for CB1 is
Figure 3. Distribution of CB1 receptors in the lateral area of the
hypothalamus (Panel A). 3V, third ventricle. Panel B, Magnifica-
tion of the area within the square in panel A showing the location
of CB1-r immunoreactivity. S, Neuronal soma immunostained for
CB1; arrows indicate neuronal fibers immunostained for CB1.
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7.49 and 89 nM, respectively (36). Therefore, the dose of
AM251 (500 ng/5 μL, 180 μM) used was 10-fold higher
than the dose of AEA (50 ng/5 μL, 28 μM), resulting in
affinity binding of the antagonist exceeding at least 100
times the agonist, ensuring the blockade of the receptors.
Also, abundant CB2 receptor immunoreactivity in neuronal
and glial processes was detected in the brain (37). How-
ever, we observed that the CB2 receptor antagonist, AM630
(500 ng/5 μL), injected icv did not affect the inhibitory effect
of AEA on MC-induced salivary secretion, showing that
CB2 receptors are probably not involved in the central
control of salivation. Also, TRPV1 channels can be acti-
vated by AEA and were reported to be located in the brain
(23,38). Therefore, they could be implicated in this inhibito-
ry modulation. However, we observed that capsazepine, a
TRPV1 selective antagonist, injected icv did not prevent
the inhibitory effect of AEA on salivary secretion.
Mitoh et al. (39) demonstrated that superior salivatory
neurons located in the lateral reticular formation receive
excitatory (glutamatergic) and inhibitory (GABAergic) syn-
aptic transmission in rats, and that the activation of GABAA
receptors produces hyperpolarization in mature neurons
that probably leads to the reduction of salivary secretion
(40). Our results suggest that CB1 receptors respond to
AEA by increasing GABAergic neurotransmission, since
bicuculline, a GABAA receptor antagonist, injected icv,
totally blocked the inhibitory effect of AEA on salivary
secretion. Moreover, we demonstrated previously that
GABA release was increased in hypothalamic extracts
exposed in vitro to AEA (25). Therefore, our results consti-
tute a relevant contribution to support the participation of
endocannabinoids and GABA in the control of salivary
secretion. In summary, endocannabinoids inhibit salivary
secretion by acting at least at two different levels: a) on
cannabinoid receptors in the salivary glands (18) and b) on
central CB1 receptors that respond by inhibiting parasym-
pathetic neurotransmission to the salivary glands.
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